Geospatial analysis of type B and C hepatitis in South Sulawesi
Abstract
Introduction: Hepatitis C and B are two infectious diseases that increase distribution and high mortality and morbidity. Conditions that exacerbate the economic burden of these two viral hepatitis infections are complications of cirrhosis and gastrointestinal bleeding. This study sought to assess the risk levels of hepatitis C and B across various districts and cities in South Sulawesi. It involved identifying spatial clusters of affected individuals through an analytical model, employing Generalized Poisson Regression to evaluate the potential impacts of these viral infections. Methods: The natural break method is a quantifiable technique for identifying value clusters indicative of data distribution and for detecting geographical illness clusters, using Global Moran’s I statistics. This research utilizes data from health insurance members diagnosed with hepatitis C and B between January 2020 and December 2022, including 24 districts and cities in South Sulawesi Province. Results: According to the results of the Local Morans I analysis, there is no significant clustered hepatitis C and B in all districts and cities in South Sulawesi from 2020 until 2022. Conclusions: In South Sulawesi, the incidence of hepatitis C and B cases reported to National Social Health Insurance Administration Body (BPJS Kesehatan) appeared to manifest randomly or sporadically.
References
1. Colzani E. Beyond morbidity and mortality: the burden of infectious diseases on healthcare services. Epidemiol Infect. 2019;147:e251.
2. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology & Hepatology. 2022;7(5):396–415.
3. Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: a systematic review and meta‐analysis. Journal of gastroenterology and hepatology. 2019;34(2):321–9.
4. Gomes C, Wong RJ, Gish RG. Global perspective on hepatitis B virus infections in the era of effective vaccines. Clinics in liver disease. 2019;23(3):383–99.
5. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology. 2022;7(9):796–829.
6. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. The Lancet. 2019;393(10179):1453–64.
7. Koffas A, Kennedy PT. Hepatitis B and D. Medicine. 2019;47(11):746–51.
8. Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World journal of gastroenterology. 2019;25(29):3929.
9. Sagnelli C, Sica A, Creta M, Calogero A, Ciccozzi M, Sagnelli E. Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years. World Journal of Gastroenterology. 2022;28(26):3081.
10. Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. International Journal of Epidemiology. 2021;50(2):560–9.
11. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clinics and Research in Hepatology and Gastroenterology. 2021 May;45(3):101596.
12. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. International journal of molecular sciences. 2019;20(6):1358.
13. Oktaria V, Mahendradhata Y. The health status of Indonesia’s provinces: the double burden of diseases and inequality gap. The Lancet Global Health. 2022;10(11):e1547–8.
14. Solomay T, Semenenko T. Viral hepatitis B, C and infectious mononucleosis: epidemiological similarities and differences. Problems of Virology. 2020;65(1):27–34.
15. Stasi C, Silvestri C, Voller F. Update on hepatitis C epidemiology: unaware and untreated infected population could be the key to elimination. SN comprehensive clinical medicine. 2020;2:2808–15.
16. Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, et al. Epidemiological and clinical characteristics of hepatitis C virus infection in South Korea from 2007 to 2017: a prospective multicenter cohort study. Gut and Liver. 2020;14(2):207.
17. Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2021;6(2):106–19.
18. Flores JE, Thompson AJ, Ryan M, Howell J. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines. 2022 May 17;10(5):793.
19. Ghany MG, Morgan TR, AASLD‐IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb;71(2):686–721.
20. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Mar 18;33(2):e00046-19.
21. Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. 2019;156(2):297–310.
22. Premkumar M, Anand AC. Overview of complications in cirrhosis. Journal of Clinical and Experimental Hepatology. 2022;
23. Jaffe A, Lim JK, Jakab SS. Pathophysiology of hepatic encephalopathy. Clinics in Liver Disease. 2020;24(2):175–88.
24. Weng W zhen, Chen J feng, Peng X hua, Huang M, Zhang J, Xiong J, et al. Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure. Epidemiol Infect. 2022;150:e147.
25. Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of decompensated hepatitis B cirrhosis: current status and challenges. BioMed Research International. 2020;2020.
26. Tanaka J, Akita T, Ko K, Miura Y, Satake M, Epidemiological Research Group on Viral Hepatitis and its Long ‐term Course, Ministry of Health, Labour and Welfare of Japan. Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view. Hepatology Research. 2019 Sep;49(9):990–1002.
27. Voulgaris T, Karagiannakis D, Siakavellas S, Kalogera D, Angelopoulos T, Chloupi E, et al. High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. Annals of Gastroenterology. 2019;32(5):451.
28. Rehman ST, Rehman H, Abid S. Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. World Journal of Hepatology. 2021;13(7):781.
29. Chen B, Wang M, Huang X, Xie M, Pan L, Liu H, et al. Changes in incidence of notifiable infectious diseases in China under the prevention and control measures of COVID-19. Frontiers in public health. 2021;9:728768.
30. Yan X, Wang X, Zhang X, Wang L, Zhang B, Jia Z. The epidemic of sexually transmitted diseases under the influence of COVID-19 in China. Frontiers in public health. 2021;9:737817.
31. Pley CM, McNaughton AL, Matthews PC, Lourenço J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Global Health. 2021;6(1):e004275.
32. Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol. 2022 Nov 7;28(41):5910–30.
33. Mantovani A, Tsochatzis EA. Epidemiology of varices and variceal bleeding in liver cirrhosis. Variceal Bleeding in Liver Cirrhosis. 2021;1–11.
34. Wang M, Li C, Liang L, Xing H, Sun L, Quan B, et al. Early and late recurrence of hepatitis B virus‐associated hepatocellular carcinoma. The oncologist. 2020;25(10):e1541–51.
35. Alsahhar JS, Elwir S. Epidemiology and natural history of chronic liver disease. The Critically Ill Cirrhotic Patient: Evaluation and Management. 2020;1–9.
36. Trifan A. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: a propensity score analysis. MSJ. 2021 Mar 30;125(1):54–64.
37. Liu H, Sun J, Liu X, Liu G, Zhou Q, Deng J, et al. Dual-energy computed tomography for non-invasive prediction of the risk of oesophageal variceal bleeding with hepatitis B cirrhosis. Abdom Radiol. 2021 Nov;46(11):5190–200.
38. Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. Drugs. 2021 Apr;81(6):647–67.
39. Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells. 2019;8(10):1249.
40. Yue M. Unsolved challenges in hepatitis B and hepatitis C: from prevention to treatment. Frontiers in Cellular and Infection Microbiology. 2023;13.
41. Yunihastuti E, Ratih DM, Aisyah MR, Hidayah AJ, Widhani A, Sulaiman AS, et al. Needlestick and sharps injuries in an Indonesian tertiary teaching hospital from 2014 to 2017: a cohort study. BMJ open. 2020;10(12):e041494.
42. Guvenir M, Arikan A. Hepatitis B virus: from diagnosis to treatment. Polish Journal of Microbiology. 2020;69(4):391–9.
43. Atlaw D, Sahiledengle B, Tariku Z. Hepatitis B and C virus infection among healthcare workers in Africa: a systematic review and meta-analysis. Environ Health Prev Med. 2021 Dec;26(1):61.
44. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Mar 18;33(2):e00046-19.
45. Gholizadeh O, Akbarzadeh S, Ghazanfari Hashemi M, Gholami M, Amini P, Yekanipour Z, et al. Hepatitis A: viral structure, classification, life cycle, clinical symptoms, diagnosis error, and vaccination. Canadian Journal of Infectious Diseases and Medical Microbiology. 2023;2023.
46. Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clinics and Research in Hepatology and Gastroenterology. 2021 May;45(3):101626.
47. Zainuddin AA, Rahim A, Ramadany S, et al. Geospatial analysis of type 2 diabetes mellitus and hypertension in South Sulawesi, Indonesia. Sci Rep. 2023;13(1). doi:10.1038/s41598-023-27902-y
48. Anselin L, Syabri I, Kho Y. GeoDa: An introduction to spatial data analysis. Geogr Anal. 2006;38(1):5-22. doi:10.1111/j.0016-7363.2005.00671.x
49. Abdulhafedh A. A Novel Hybrid Method for Measuring the Spatial Autocorrelation of Vehicular Crashes: Combining Moran’s Index and Getis-Ord G<sub>i</sub><sup style='margin-left:-7px;'>*</sup> Statistic. Open Journal of Civil Engineering. 2017;07(02):208-221. doi:10.4236/ojce.2017.72013
50. Shenge JA, Osiowy C. Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries. Frontiers in Virology. 2021;1. doi:10.3389/fviro.2021.742722
51. Mohsen A, Hattaf K, AL-Husseiny H. Dynamical Analysis of Transmission of Hepatitis B and C Viruses with External Source of disease by Mathematical Model. Published online September 7, 2021. doi:10.21203/rs.3.rs-730763/v1
52. Naqvi IH, Talib A, Baloch G, Mahmood K, Qadari Z. HEPATITIS B AND C: FREQUENCY, MODES OF TRANSMISSION AND RISK FACTORS ALONG WITH SOME UNORTHODOX ROUTES OF SPREAD. www.pjph.org
53. Ifeorah IM, Bakarey AS, Adewumi MO, et al. Patterns of serologic markers of hepatitis B virus infection and the risk of transmission among pregnant women in southwestern Nigeria. J Immunoassay Immunochem. 2017;38(6):639-651. doi:10.1080/15321819.2017.1384389
54. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332-342. doi:10.1016/S2468-1253(22)00386-7
55. Xu M, Terrault NA. Hepatitis B Virus Elimination Strategies. Curr Hepatol Rep. 2024;23(2):268-277. doi:10.1007/s11901-024-00658-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Rini Rachmawarni Bachtiar, Andi Alfian Zainuddin, Rahmawati Minhajat1, Sri Jayanti
This work is licensed under a Creative Commons Attribution 4.0 International License.
